MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cid/ciy574

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019

Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo.

Marks Michael, Toloka Hilary, Baker Ciara, Kositz Christian, Asugeni James, Puiahi Elliot, Asugeni Rowena, Azzopardi Kristy, Diau Jason, Kaldor John M, Romani Lucia, Redman-MacLaren Michelle, MacLaren David, Solomon Anthony W, Mabey David C W, Steer Andrew C

Клиническое исследование IV фазыСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Scabies is a public health problem in many countries, with impetigo and its complications important consequences. Ivermectin based mass drug administration (MDA) reduces the prevalence of scabies and, to a lesser extent, impetigo. We studied the impact of co-administering azithromycin on the prevalence of impetigo and antimicrobial resistance.

METHODS

Six communities were randomized to receive either ivermectin-based MDA or ivermectin-based MDA co-administered with azithromycin. We measured scabies and impetigo prevalence at baseline and 12 months. We collected impetigo lesions swabs at baseline, 3 and 12 months to detect antimicrobial resistance.

RESULTS

At baseline, scabies and impetigo prevalences were 11.8% and 10.1% in the ivermectin-only arm and 9.2% and 12.1% in the combined treatment arm. At 12 months, the prevalences had fallen to 1.0% and 2.5% in the ivermectin-only arm and 0.7% and 3.3% in the combined treatment arm. The proportion of impetigo lesions containing Staphylococcus aureus detected did not change (80% at baseline vs 86% at 12 months; no significant difference between arms) but the proportion containing pyogenic streptococci fell significantly (63% vs 23%, P < .01). At 3 months, 53% (8/15) of S. aureus isolates were macrolide-resistant in the combined treatment arm, but no resistant strains (0/13) were detected at 12 months.

CONCLUSIONS

Co-administration of azithromycin with ivermectin led to similar decreases in scabies and impetigo prevalence compared to ivermectin alone. The proportion of impetigo lesions containing pyogenic streptococci declined following MDA. There was a transient increase in the proportion of macrolide-resistant S. aureus strains following azithromycin MDA.

CLINICAL TRIALS REGISTRATION: clinicaltrials.gov (NCT02775617).

Для цитирования: Marks Michael, Toloka Hilary, Baker Ciara, Kositz Christian, Asugeni James, Puiahi Elliot, Asugeni Rowena, Azzopardi Kristy, Diau Jason, Kaldor John M, Romani Lucia, Redman-MacLaren Michelle, MacLaren David, Solomon Anthony W, Mabey David C W, Steer Andrew C. Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019. DOI: 10.1093/cid/ciy574.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.